[H-3]Nemonapride differentially defines sigma and dopamine receptor sites depending upon assay conditions. In post-mortem schizophrenic brain tissues, [H-3]nemonapride-labeled sigma receptor binding is decreased compared to matched normal controls. No striatal dopamine D-4/D-4-like receptor differential was observed between the schizophrenic or control tissues, using the [H-3]nemonapride minus [H-3]raclopride subtraction method.